Prognostic significance of progesterone receptor levels in luminal-like Her2-early breast cancer patients. A retrospective single cancer center analysis

被引：0
|
作者：
Diana, A. [1 ]
Carlino, F. [1 ]
Franzese, E. [1 ]
Centonze, S. [1 ]
Guerrera, L. P. [1 ]
Perrone, A. [1 ]
De Vita, F. [1 ]
Ciardiello, F. [1 ]
Orditura, M. [1 ]
机构：
[1] Univ Campania Luigi Vanvitelli, Dept Precis Med, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
247P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Progesterone Receptor and HER2 Status Are Significant Prognostic Factors in Advanced Breast Cancer
    Ren, Z.
    Hameed, O.
    Li, Y.
    Siegal, G. P.
    Wei, S.
    LABORATORY INVESTIGATION, 2012, 92 : 62A - 62A
  • [42] Progesterone Receptor and HER2 Status Are Significant Prognostic Factors in Advanced Breast Cancer
    Ren, Z.
    Hameed, O.
    Li, Y.
    Sieged, G. P.
    Wei, S.
    MODERN PATHOLOGY, 2012, 25 : 62A - 62A
  • [43] Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers
    Kaolu Sato
    Minoru Miyashita
    Takanori Ishida
    Akihiko Suzuki
    Hiroshi Tada
    Go Watanabe
    Akiko Sato-Tadano
    Mika Watanabe
    Noriaki Ohuchi
    Breast Cancer, 2016, 23 : 310 - 317
  • [44] Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers
    Sato, Kaolu
    Miyashita, Minoru
    Ishida, Takanori
    Suzuki, Akihiko
    Tada, Hiroshi
    Watanabe, Go
    Sato-Tadano, Akiko
    Watanabe, Mika
    Ohuchi, Noriaki
    BREAST CANCER, 2016, 23 (02) : 310 - 317
  • [45] Prognostic and biologic significance of HER2-low expression in early breast cancer
    Tarantino, P.
    Jin, Q.
    Tayob, N.
    Jeselsohn, R.
    Schnitt, S. J.
    Vincuilla, J.
    Parker, T.
    Tyekucheva, S.
    Lin, N. U.
    Hughes, M.
    Weiss, A. C.
    King, T. A.
    Mittendorf, E. A.
    Curigliano, G.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 : S124 - S124
  • [46] Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
    Van Asten, Kathleen
    Slembrouck, Laurence
    Olbrecht, Siel
    Jongen, Lynn
    Brouckaert, Olivier
    Wildiers, Hans
    Floris, Giuseppe
    Van Limbergen, Erik
    Weltens, Caroline
    Smeets, Ann
    Paridaens, Robert
    Giobbie-Hurder, Anita
    Regan, Meredith M.
    Viale, Giuseppe
    Thurlimann, Beat
    Vergote, Ignace
    Christodoulou, Evangelia
    Van Calster, Ben
    Neven, Patrick
    ONCOLOGIST, 2019, 24 (02): : 165 - 171
  • [47] Prognostic factors in Luminal B-like HER2-negative breast cancer tumors
    Castellarnau-Visus, Marta
    Soveral, Iris
    Espin, Purificacion Regueiro
    Manzano, Juncal Pineros
    Holgado, Maria Del Rio
    SURGICAL ONCOLOGY-OXFORD, 2023, 49
  • [48] TRASTUZUMAB IN HER2 POSITIVE EARLY BREAST CANCER: A RETROSPECTIVE AUDIT IN A REGIONAL CANCER CENTER
    Heng, Sharon
    Pokharel, Khageshwor
    Gilbar, Peter
    Tannock, Margot
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 153 - 153
  • [49] Exploring the predictive and prognostic significance of HER2 in HER2negative early breast cancer
    Coriano, M.
    Battisti, N. M. L.
    Aziz, H.
    Hogan, N. Joharatnam
    Turkes, F.
    Cunningham, N.
    Needham, J.
    Sun, M.
    Waterhouse, J.
    Tommasi, C.
    Musolino, A.
    Ring, A.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 28 - 28
  • [50] Should estrogen receptor positive and progesterone receptor negative and HER-2 negative breast cancer patients be considered as a luminal B subtype?
    Altundag, Kadri
    JOURNAL OF BUON, 2020, 25 (05): : 2529 - 2529
12345